ClinicalTrials.gg
CompletedNCT03987074Updated Jul 15, 2021Results posted

Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)

A Phase 2 interventional study of Semaglutide and Firsocostat in Nonalcoholic Steatohepatitis, sponsored by Gilead Sciences. Completed at 18 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-07-15.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
109
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences — none open to participants now, none under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · Gilead Sciences.

Enrollment
13th of 16
109 · median 161
Started
2019
the only one that year
Phase 2
11 of 16
none open now
Registered
15th of 16
by date

Among the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences, this one is the 13th largest by enrollment, is the only one that started in 2019, is one of 11 in phase 2, and was the 15th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

None of the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences as a file.
02

Study summary

The primary objective of this study is to evaluate the safety and tolerability of study drug(s) in participants with nonalcoholic steatohepatitis (NASH).

03

Conditions studied

  • Nonalcoholic Steatohepatitis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Historical liver consistent with NASH with stage 2-3 fibrosis according to NASH Clinical Research Network (CRN) classification OR clinical diagnosis of nonalcoholic fatty liver disease and screening FibroTest, magnetic resonance imaging - proton density fat fraction (MRI-PDFF), and FibroScan
  • Screening laboratory parameters, as determined by central laboratory:

    • (ALT) ≤ 5 x (ULN)
    • Estimated (eGFR) ≥ 30 milliliter/minute (mL/min), as calculated by the Modification of Diet in Renal Disease (MDRD) study equation
    • ≤ 9.5%
    • (INR) ≤ 1.2, unless due to therapeutic anti-coagulation therapy
    • count ≥ 100,000/μL
    • Total \< 1.3 x ULN unless alternate etiology such as Gilbert's syndrome present
    • Calcitonin ≤ 100 ng/L
  • (BMI) > 23 kg/m\^2 and body weight of > 60 kg

Key Exclusion Criteria:

  • Any historical liver biopsy consistent with cirrhosis
  • Any history of decompensated liver disease, including ascites, hepatic encephalopathy, or variceal bleeding
  • Other causes of liver disease, including but not limited to: alcoholic liver disease, , , disorders (eg, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), autoimmune hepatitis), drug-induced hepatotoxicity, Wilson disease, iron overload, or alpha-1-antitrypsin deficiency requiring treatment
  • History of liver transplantation
  • History of hepatocellular carcinoma
  • History of pancreatitis (acute or chronic)
  • Personal or first degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma
  • Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RA) in the period from 90 days prior to the date of the Screening Visit
  • Individuals on antidiabetic medications must be on a stable dose for at least 90 days prior to the date of the Screening Visit and in the period between the date of the Screening Visit and Enrollment (Day -14)

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
109 participants (actual)

Study arms

  • Experimental
    Semaglutide

    Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) for 24 weeks

    Drug: Semaglutide

  • Experimental
    Semaglutide + Firsocostat 20 mg

    Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + firsocostat 20 mg for 24 weeks

    Drug: Semaglutide · Drug: Firsocostat

  • Experimental
    Semaglutide + Cilofexor 30 mg

    Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + cilofexor 30 mg for 24 weeks

    Drug: Semaglutide · Drug: Cilofexor

  • Experimental
    Semaglutide + Cilofexor 100 mg

    Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + cilofexor 100 mg for 24 weeks

    Drug: Semaglutide · Drug: Cilofexor

  • Experimental
    Semaglutide + Firsocostat 20 mg + Cilofexor 30 mg

    Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + firsocostat 20 mg + cilofexor 30 mg for 24 weeks

    Drug: Semaglutide · Drug: Firsocostat · Drug: Cilofexor

Interventions

  • Solution administered subcutaneously with pre-filled PDS290 pen-injector once weekly

  • Tablets administered orally once daily

    Also known as: GS-0976

  • Tablets administered orally once daily

    Also known as: GS-9674

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)

    Treatment-emergent adverse events (TEAEs) were defined as, any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug or any AEs leading to premature discontinuation of study drug. Participants were assessed for AEs according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: First dose date up to Week 24 plus 30 days

  2. Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities

    Treatment-emergent laboratory abnormalities, defined as values that increase at least one toxicity grade from baseline at any time post-baseline up to and including the date of last dose of study drug plus 30 days, were summarized by treatment group. Graded laboratory abnormalities were defined using the grading scheme in the CTCAE 5.0.

    Time frame: First dose date up to 24 weeks plus 30 days

07

Results

Posted Jul 15, 2021

Participant flow

Participants were enrolled at study sites in United States. The first participant was screened on 29 July 2019. The last study visit occurred on 13 July 2020.

Participant flow — Overall Study
MilestoneSemaglutideSemaglutide + Firsocostat 20 mgSemaglutide + Cilofexor 30 mgSemaglutide + Cilofexor 100 mgSemaglutide + Firsocostat 20 mg + Cilofexor 30 mg
Started2122222221
Completed1820211819
Not completed32142
Withdrew: Withdrew consent11021
Withdrew: Adverse event21001
Withdrew: Lost to follow-up00110
Withdrew: Investigator's discretion00010

Outcome measures

PrimaryPercentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)

Treatment-emergent adverse events (TEAEs) were defined as, any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug or any AEs leading to premature discontinuation of study drug. Participants were assessed for AEs according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

Time frame:
First dose date up to Week 24 plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
percentage of participantsSemaglutideSemaglutide + Firsocostat 20 mgSemaglutide + Cilofexor 30 mgSemaglutide + Cilofexor 100 mgSemaglutide + Firsocostat 20 mg + Cilofexor 30 mg
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)81.086.481.872.790.5
PrimaryPercentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities

Treatment-emergent laboratory abnormalities, defined as values that increase at least one toxicity grade from baseline at any time post-baseline up to and including the date of last dose of study drug plus 30 days, were summarized by treatment group. Graded laboratory abnormalities were defined using the grading scheme in the CTCAE 5.0.

Time frame:
First dose date up to 24 weeks plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities
percentage of participantsSemaglutideSemaglutide + Firsocostat 20 mgSemaglutide + Cilofexor 30 mgSemaglutide + Cilofexor 100 mgSemaglutide + Firsocostat 20 mg + Cilofexor 30 mg
Grade 161.963.636.450.066.7
Grade 223.822.731.818.29.5
Grade 30.04.50.00.00.0
Grade 40.00.00.09.10.0

Adverse events

Collected over First dose date up to 24 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Semaglutide0/21 (0%)1/21 (4.8%)16/21 (76.2%)
Semaglutide + Firsocostat 20 mg0/22 (0%)0/22 (0%)17/22 (77.3%)
Semaglutide + Cilofexor 30 mg0/22 (0%)0/22 (0%)18/22 (81.8%)
Semaglutide + Cilofexor 100 mg0/22 (0%)1/22 (4.5%)13/22 (59.1%)
Semaglutide + Firsocostat 20 mg + Cilofexor 30 mg0/21 (0%)0/21 (0%)17/21 (81%)
Most frequent serious events
Most frequent serious events
EventSemaglutideSemaglutide + Firsocostat 20 mgSemaglutide + Cilofexor 30 mgSemaglutide + Cilofexor 100 mgSemaglutide + Firsocostat 20 mg + Cilofexor 30 mg
DiarrhoeaGastrointestinal disorders1/210/220/220/220/21
VomitingGastrointestinal disorders1/210/220/220/220/21
PancreatitisGastrointestinal disorders0/210/220/221/220/21
Most frequent other events
Showing 10 of 29
Most frequent other events
EventSemaglutideSemaglutide + Firsocostat 20 mgSemaglutide + Cilofexor 30 mgSemaglutide + Cilofexor 100 mgSemaglutide + Firsocostat 20 mg + Cilofexor 30 mg
NauseaGastrointestinal disorders9/213/228/226/2214/21
VomitingGastrointestinal disorders1/212/222/221/226/21
Decreased appetiteMetabolism and nutrition disorders4/214/226/220/223/21
ConstipationGastrointestinal disorders2/212/225/223/225/21
DiarrhoeaGastrointestinal disorders5/214/225/221/223/21
ArthralgiaMusculoskeletal and connective tissue disorders5/210/220/222/220/21
Abdominal painGastrointestinal disorders1/214/221/221/222/21
Gastrooesophageal reflux diseaseGastrointestinal disorders0/214/221/220/220/21
HypoglycaemiaMetabolism and nutrition disorders0/212/224/220/220/21
Abdominal pain upperGastrointestinal disorders3/211/221/220/222/21

Baseline characteristics

The Safety Analysis Set included participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)SemaglutideSemaglutide + Firsocostat 20 mgSemaglutide + Cilofexor 30 mgSemaglutide + Cilofexor 100 mgSemaglutide + Firsocostat 20 mg + Cilofexor 30 mgTotal
Mean55 ± 10.452 ± 12.651 ± 10.954 ± 10.853 ± 11.453 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)SemaglutideSemaglutide + Firsocostat 20 mgSemaglutide + Cilofexor 30 mgSemaglutide + Cilofexor 100 mgSemaglutide + Firsocostat 20 mg + Cilofexor 30 mgTotal
Female151516131574
Male6769634
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SemaglutideSemaglutide + Firsocostat 20 mgSemaglutide + Cilofexor 30 mgSemaglutide + Cilofexor 100 mgSemaglutide + Firsocostat 20 mg + Cilofexor 30 mgTotal
American Indian or Alaska Native101114
Asian222107
Black101103
White171918191992
Other010012
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SemaglutideSemaglutide + Firsocostat 20 mgSemaglutide + Cilofexor 30 mgSemaglutide + Cilofexor 100 mgSemaglutide + Firsocostat 20 mg + Cilofexor 30 mgTotal
Not Hispanic or Latino131017151065
Hispanic or Latino812571143
08

Study locations

18 sites
  • Institute for Liver Health - Arizona Liver Health
    Chandler, Arizona 85224, United States
  • Southern California Research Centers
    Coronado, California 92118, United States
  • University of California San Diego (UCSD)
    La Jolla, California 92093, United States
  • Ruane Clinical Research Group, Inc
    Los Angeles, California 90036, United States
  • Cedars Sinai Medical Center
    Los Angeles, California 90048, United States
  • Inland Empire Clinical Trials, LLC
    Rialto, California 92377, United States
  • Medical Associates Research Group
    San Diego, California 92123, United States
  • Gastrointestinal Specialists of Georgia
    Marietta, Georgia 30060, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Jubilee Clinical Research, Inc.
    Las Vegas, Nevada 89109, United States
  • Northwell Health
    Manhasset, New York 11030, United States
  • Gastro One
    Huntersville, North Carolina 28078, United States
  • University Gastroenterology
    Providence, Rhode Island 02905, United States
  • Gastro One
    Germantown, Tennessee 38138, United States
  • Quality Medical Research, PLLC
    Nashville, Tennessee 37211, United States
  • Texas Clinical Research Institute
    Arlington, Texas 76012, United States
  • The Liver Institute at Methodist Dallas Medical Center
    Dallas, Texas 75203, United States
  • American Research Corporation
    San Antonio, Texas 78215, United States
09

References and documents

Publications

  • Alkhouri N et al. Safety and Efficacy of Combination Therapies Including Semaglutide, Cilofexor, and Firsocostat in Patients with NASH [accepted for oral presentation]. American Association for the Study of Liver Diseases (AASLD); 2020; Virtual.
  • Alkhouri N, Herring R, Kabler H, Kayali Z, Hassanein T, Kohli A, Huss RS, Zhu Y, Billin AN, Damgaard LH, Buchholtz K, Kjaer MS, Balendran C, Myers RP, Loomba R, Noureddin M. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. J Hepatol. 2022 Sep;77(3):607-618. doi: 10.1016/j.jhep.2022.04.003. Epub 2022 Apr 16. PubMed 35439567 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Jul 2020, 11 months.

Results were first posted in Jul 2021, 1 year after primary completion.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 11 months is below that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2019
First posted
Jun 14, 2019
StartActual
Jul 29, 2019
Primary completionActual
Jul 13, 2020
CompletionActual
Jul 13, 2020
Results first posted
Jul 15, 2021
Last update
Jul 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03987074
Lead sponsor
Gilead Sciences
Collaborators
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jun 14, 2019
Start date
Jul 29, 2019
Primary completion
Jul 13, 2020
Completion
Jul 13, 2020
Results posted
Jul 15, 2021
Last update
Jul 15, 2021

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Firsocostat · Cilofexor

Start the discussion